Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Primary Dysautonomias

ClinicalTrials.gov lists 731 trials for Primary Dysautonomias or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 15.

MeSH D054969 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 63 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 71 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 31 Phase 4 Phase 4 29 Not applicable Not applicable 300 Observational Observational 211 Phase 1 Phase 1 63 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 71 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 31 Phase 4 Phase 4 29 Not applicable Not applicable 300 Observational Observational 211

Trials per phase (log scale)

1 more section with rows

131 of the 731 trials are tagged with Primary Dysautonomias itself; the rest are tagged with a narrower condition beneath it.

Get the Primary Dysautonomias report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Primary Dysautonomias trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 67

1992: 1 trials (Observational 1) 1994: 1 trials (Observational 1) 1995: 2 trials (Observational 2) 1996: 2 trials (Not applicable 1, Phase 1 1) 1997: 2 trials (Phase 4 1, Phase 1/2 1) 1999: 1 trials (Not applicable 1) 2000: 1 trials (Phase 3 1) 2001: 3 trials (Not applicable 1, Phase 2 1, Phase 1 1) 2002: 4 trials (Not applicable 2, Phase 4 1, Phase 1 1) 2003: 7 trials (Observational 4, Phase 4 1, Phase 2/3 1, Phase 1 1) 2004: 9 trials (Not applicable 3, Phase 4 1, Phase 2/3 1, Phase 2 3, Phase 1 1) 2005: 4 trials (Not applicable 2, Phase 4 1, Phase 1 1) 2006: 11 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 2/3 1, Phase 2 3) 2007: 11 trials (Observational 5, Not applicable 3, Phase 2 1, Phase 1/2 1, Phase 1 1) 2008: 17 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 6) 2009: 19 trials (Observational 7, Not applicable 6, Phase 3 2, Phase 2 2, Phase 1 2) 2010: 22 trials (Observational 10, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 2) 2011: 19 trials (Observational 7, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 2012: 24 trials (Observational 9, Not applicable 6, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1/2 1, Phase 1 3) 2013: 20 trials (Observational 6, Not applicable 10, Phase 3 2, Phase 2 1, Phase 1 1) 2014: 28 trials (Observational 8, Not applicable 9, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1/2 1, Phase 1 3) 2015: 23 trials (Observational 2, Not applicable 14, Phase 2/3 1, Phase 2 5, Phase 1 1) 2016: 23 trials (Observational 7, Not applicable 10, Phase 4 2, Phase 1 4) 2017: 32 trials (Observational 11, Not applicable 17, Phase 2/3 1, Phase 2 1, Phase 1 2) 2018: 37 trials (Observational 9, Not applicable 18, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1/2 2, Phase 1 3) 2019: 37 trials (Observational 12, Not applicable 13, Phase 4 2, Phase 3 5, Phase 2 3, Phase 1 2) 2020: 28 trials (Observational 6, Not applicable 12, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1 5) 2021: 48 trials (Observational 12, Not applicable 26, Phase 2 6, Phase 1 4) 2022: 67 trials (Observational 19, Not applicable 36, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1 4) 2023: 55 trials (Observational 11, Not applicable 30, Phase 4 2, Phase 3 1, Phase 2 7, Phase 1 4) 2024: 63 trials (Observational 21, Not applicable 28, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 9, Phase 1 2) 2025: 58 trials (Observational 18, Not applicable 28, Phase 4 1, Phase 2 5, Phase 1/2 1, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 46
2025 58
2024 63
2023 55
2022 67
2021 48
2020 28
2019 37
2018 37
2017 32

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 57 trials starting in 2026 and about 55 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 112 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 369 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Primary Dysautonomias trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 63
Phase 1/2 12
Phase 2 71
Phase 2/3 11
Phase 3 31
Phase 4 29
Not applicable 300
Observational 211
Expanded access 3

How many Primary Dysautonomias trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 39
Recruiting 148
Enrolling by invitation 15
Active, not recruiting 54
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Primary Dysautonomias trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Neurological Disorders and Stroke (NINDS) 15
James J. Peters Veterans Affairs Medical Center 8
Chelsea Therapeutics 6
MODAG GmbH 6

Which drugs are being tested for Primary Dysautonomias? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Droxidopa 18
Pyridostigmine 7
Ampreloxetine 5
Carbidopa 4
PHENYLEPHRINE 3

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Midodrine 2.5 mg tab 23
Exercise 7
Propranolol PO 6
Atomoxetine arm 6
Metoprolol XL 4

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Primary Dysautonomias trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Hospitalization 48 1
Cardiac Arrhythmia - Atrial Fibrillation 41 1
Urinary tract infection 36 11
Pneumonia 34 12
Death 29 7

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Primary Dysautonomias? (32)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Assessing Full Stomach Prevalence with Ultrasound Following Preoperative Fasting in Diabetic Patients with Dysautonomia: A Comparative Observational Study. Anesthesia and analgesia 2024 Yes
Heart rate variability responses to cognitive stress in fibromyalgia are characterised by inadequate autonomous system stress responses: a clinical trial. Scientific reports 2023 Yes
Cardiac autonomic dysfunction and risk of incident stroke among adults with type 2 diabetes. European stroke journal 2023 Yes
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. Journal of Parkinson's disease 2023 Yes
Hypoglycemia and Dysautonomia After Bariatric Surgery: a Systematic Review and Perspective. Obesity surgery 2022 Yes

Showing 5 of 32 publications.

Start your 14-day trial Email me all 32 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages